These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

448 related articles for article (PubMed ID: 24415364)

  • 21. Rebound hypercalcemia post-denosumab cessation in metastatic breast cancer.
    Wang R; Renouf DA
    Osteoporos Int; 2022 Jul; 33(7):1625-1629. PubMed ID: 35286436
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Rapid progression of vascular and soft tissue calcification while being managed for severe and persistent hypocalcemia induced by denosumab treatment in a patient with multiple myeloma and chronic kidney disease.
    Ueki K; Yamada S; Tsuchimoto A; Tokumoto M; Kumano T; Kitazono T; Tsuruya K
    Intern Med; 2015; 54(20):2637-42. PubMed ID: 26466702
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Hypercalcemic complication in patients with oral squamous cell carcinoma.
    Iwase M; Takemi T; Manabe M; Nagumo M
    Int J Oral Maxillofac Surg; 2003 Apr; 32(2):174-80. PubMed ID: 12729778
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Hypocalcemia post denosumab in patients with chronic kidney disease stage 4-5.
    Dave V; Chiang CY; Booth J; Mount PF
    Am J Nephrol; 2015; 41(2):129-37. PubMed ID: 25790847
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Hypercalcaemia-induced acute kidney injury in an older patient with osteoporosis treated with alfacalcidol for denosumab-induced hypocalcaemia.
    Yamada S; Matsuo M; Tokumoto M; Ooboshi H
    Nephrology (Carlton); 2017 Jul; 22(7):572-573. PubMed ID: 28621008
    [No Abstract]   [Full Text] [Related]  

  • 26. [Medical treatment of malignant hypercalcemia].
    Eto S; Nakano Y; Okada Y
    Gan To Kagaku Ryoho; 1993 Dec; 20(15):2311-8. PubMed ID: 8259844
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Effects of denosumab on hypercalcemia and bone mineral density loss in kidney transplant recipients
.
    Nanmoku K; Shinzato T; Kubo T; Shimizu T; Yagisawa T
    Clin Nephrol; 2019 Jul; 92(1):1-8. PubMed ID: 30990412
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Refractory hypercalcaemia secondary to parathyroid carcinoma: response to high-dose denosumab.
    Karuppiah D; Thanabalasingham G; Shine B; Wang LM; Sadler GP; Karavitaki N; Grossman AB
    Eur J Endocrinol; 2014 Jul; 171(1):K1-5. PubMed ID: 24743399
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Pharmaceutical Intervention According to Strict Management System Can Normalize Decreased Serum Calcium Level by Denosumab and Prevent Its Aggravation].
    Saito Y; Uchiyama K; Sakamoto T; Yamazaki K; Kubota K; Takekuma Y; Komatsu Y; Sugawara M
    Yakugaku Zasshi; 2021; 141(8):1023-1030. PubMed ID: 34334547
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Denosumab should be the treatment of choice for bisphosphonate refractory hypercalcaemia of malignancy.
    Adhikaree J; Newby Y; Sundar S
    BMJ Case Rep; 2014 Jan; 2014():. PubMed ID: 24481018
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Onco-nephrology: the pathophysiology and treatment of malignancy-associated hypercalcemia.
    Rosner MH; Dalkin AC
    Clin J Am Soc Nephrol; 2012 Oct; 7(10):1722-9. PubMed ID: 22879438
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Hypercalcemia, symptoms, differential diagnostics and treatment, or importance of calcium investigation].
    Adam Z; Starý K; Kubinyi J; Zajíčková K; Řehák Z; Koukalová R; Tomíška M; Doubková M; Prášek J; Pourová E; Čermáková Z; Pour L; Krejčí M; Sandecká V; Ševčíková E; Ševčíková S; Král Z; Čermák A
    Vnitr Lek; 2016; 62(5):370-83. PubMed ID: 27319230
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Incidence of skeletal related events in patients with bone metastasis receiving denosumab every four weeks compared to intervals greater than every four weeks.
    Yerram P; Moore R; Wolf S; Barbour SY
    J Oncol Pharm Pract; 2019 Apr; 25(3):529-534. PubMed ID: 29207934
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Hypocalcaemic tetany occurring post a single denosumab dose in a patient with stage 4 chronic kidney disease, followed by calcium- and calcitriol-induced hypercalcaemia.
    Lambe G; Malvathu R; Thomas HM; Graves A
    Nephrology (Carlton); 2015 Aug; 20(8):583-4. PubMed ID: 26194986
    [No Abstract]   [Full Text] [Related]  

  • 35. Use of high-dose denosumab in the management of immobilization-related hypercalcemia in an end-stage renal disease patient on hemodialysis: A case report and review of the literature.
    Zaitoun MF; Al-Alsheikh KA; Elnazer W
    Clin Nephrol; 2021 Dec; 96(6):353-356. PubMed ID: 34605398
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Tolerability of denosumab in metastatic solid tumor patients with renal insufficiency.
    Watkins KR; Rogers JE; Atkinson B
    Support Care Cancer; 2015 Jun; 23(6):1657-62. PubMed ID: 25421444
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Protracted hypocalcaemia following a single dose of denosumab in humoral hypercalcaemia of malignancy due to PTHrP-secreting neuroendocrine tumour.
    Teng J; Abell S; Hicks RJ; Hofman MS; Sachithanandan N; McKelvie P; MacIsaac RJ
    Clin Endocrinol (Oxf); 2014 Dec; 81(6):940-2. PubMed ID: 24890549
    [No Abstract]   [Full Text] [Related]  

  • 38. Malignancy associated hypercalcaemia-responsiveness to IV bisphosphonates and prognosis in a palliative population.
    Mallik S; Mallik G; Macabulos ST; Dorigo A
    Support Care Cancer; 2016 Apr; 24(4):1771-7. PubMed ID: 26441077
    [TBL] [Abstract][Full Text] [Related]  

  • 39. High serum ALP level is associated with increased risk of denosumab-related hypocalcemia in patients with bone metastases from solid tumors.
    Kinoshita Y; Arai M; Ito N; Takashi Y; Makita N; Nangaku M; Shinoda Y; Fukumoto S
    Endocr J; 2016 May; 63(5):479-84. PubMed ID: 26860123
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Hypocalcaemia after denosumab in older people following fracture.
    Chen J; Smerdely P
    Osteoporos Int; 2017 Feb; 28(2):517-522. PubMed ID: 27682248
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 23.